Taltz ® (ixekizumab) injection

80 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

TALTZ® (ixekizumab): Delivery Devices and Administration

Ixekizumab is available both as an autoinjector and prefilled syringe for subcutaneous administration.

Delivery Devices

Ixekizumab is available both as an autoinjector and prefilled syringe for SC administration.1

Ixekizumab is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in SC injection technique using the autoinjector or prefilled syringe.1

Administration

Each ixekizumab injection is to be administered

  • at a different anatomic location (such as upper arms, thighs, or any quadrant of the abdomen) than the previous injection, and

  • not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.1

Administration into the upper outer arm may be performed by a caregiver or healthcare provider.1

Preparation and Use

Before injection, remove the autoinjector or prefilled syringe from the refrigerator and allow ixekizumab to reach room temperature (30 minutes) without removing the needle cap.1

Inspect ixekizumab visually for particulate matter and discoloration prior to administration. The ixekizumab solution should appear clear and colorless to slightly yellow. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).1

Ixekizumab does not contain preservatives, therefore discard any unused product remaining in the autoinjector or prefilled syringe.1

Instruct patients using the autoinjector or prefilled syringe to inject the full amount (1 mL), which provides 80 mg of ixekizumab, according to the directions provided in the instructions for use.1

Each autoinjector and prefilled syringe contain a single-dose (80 mg/mL) solution of ixekizumab.1

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.

Glossary

SC = subcutaneous

Date of Last Review: April 08, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical